Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17393699 | 0.78 | RECQL (0.34) | — | |
| SCHEMBL14243736 | 0.73 | PIK3CD (0.32) | PIK3CD | |
| SCHEMBL14243735 | 0.73 | PIK3CD (0.32) | PIK3CD | |
| SCHEMBL11715 | 0.69 | — | — | |
| SCHEMBL18909657 | 0.69 | LTA4H (0.33) | — | |
| SCHEMBL1487899 | 0.68 | — | — | |
| SCHEMBL13223749 | 0.67 | MEN1 (0.33) | — | |
| SCHEMBL8897528 | 0.67 | CYP1A2 (0.33) | — | |
| SCHEMBL450230 | 0.67 | — | — | |
| SCHEMBL1448231 | 0.67 | ALDH1A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4140991-B1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | PROMEGA CORP (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-4140991-A1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | Promega Corporation (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-3562823-B1 | FUNCTIONALIZED NANOLUC INHIBITORS | PROMEGA CORP (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20220291223-A1 | CHEMILUMINESCENT COMPOUNDS FOR MULTIPLEXING | ABBOTT LAB (US) | 2022-09-15 | — | — | US | disclosed |
| US-11390599-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | PROMEGA CORPORATION (US) | 2022-07-19 | — | — | US | disclosed |
| CN-107922428-B | Thienopyrrole compounds and their use as inhibitors of oplophorus-derived luciferase | 普洛麦格公司 | 2021-02-05 | — | — | CN | disclosed |
| US-10815247-B2 | Functionalized NANOLUC inhibitors | PROMEGA CORPORATION (US) | 2020-10-27 | — | — | US | disclosed |
| EP-3313846-B1 | THIENOPYRROLE COMPOUNDS AND USES THEREOF AS INHIBITORS OF OPLOPHORUS-DERIVED LUCIFERASES | PROMEGA CORP (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20200063110-A1 | THIENOPYRROLE COMPOUNDS AND USES THEREOF | PROMEGA CORPORATION | 2020-02-27 | — | — | US | disclosed |
| US-20180222916-A1 | FUNCTIONALIZED NANOLUC INHIBITORS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20130096132-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBVIE INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-8377913-B2 | Vitamin D receptor activators and methods of making | ABBVIE INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8314119-B2 | Azaadamantane derivatives and methods of use | ABBVIE INC. (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2222635-A2 | NEW VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | Abbott Laboratories (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-2099795-A2 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | Abbott Laboratories (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2009067578-A2 | NEW VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20090131379-A1 | VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | ABBOTT LABORATORIES (US) | 2009-05-21 | — | — | US | disclosed |
| US-20080167336-A1 | Alzheimer's disease; central nervous system disorders; aids; Pick's disease; attention deficit disorder; hyperactivity; Down's syndrome, amytropic lateral sclerosis; Huntington's disease; suppression of smoking; drug abruse; brain disorders; analgesics; antiinflammatory agents | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008058096-A9 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBOTT LAB (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008058096-A2 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBOTT LABORATORIES (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131379-A1 | VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | VDR, CYP2R1, CYP24A1 | PIK3CD 322/4885 |
| US-10815247-B2 | Functionalized NANOLUC inhibitors | RNGTT, LUC7L2, GUSB | PIK3CD 1546/4885 |
| US-20180222916-A1 | FUNCTIONALIZED NANOLUC INHIBITORS | RNGTT, LUC7L2, GUSB | PIK3CD 1546/4885 |
| US-20130096132-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | GNE, CYP3A5, UGT1A4 | PIK3CD 479/4885 |
| US-20080167336-A1 | Alzheimer's disease; central nervous system disorders; aids; Pick's disease; attention deficit disorder; hyperactivity; Down's syndrome, amytropic lateral sclerosis; Huntington's disease; suppression of smoking; drug abruse; brain disorders; analgesics; antiinflammatory agents | HTT, ACHE, CHRNA10 | PIK3CD 579/4885 |
| US-11390599-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | LUC7L2, LYPLAL1, GUSB | PIK3CD 3638/4885 |
| US-20200063110-A1 | THIENOPYRROLE COMPOUNDS AND USES THEREOF | THOP1, TYMP, CREBBP | PIK3CD 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.